Yashica Narkar Ms,Rac, MBA
About Yashica Narkar Ms,Rac, MBA
Yashica Narkar is a Senior Regulatory Affairs Specialist at Silk Road Medical, Inc. in the United States, with extensive experience in regulatory affairs across multiple pharmaceutical companies.
Title
Yashica Narkar serves as Senior Regulatory Affairs Specialist at Silk Road Medical, Inc. in the United States.
Company Experience at Ethicon, Inc.
Yashica Narkar worked at Ethicon, Inc., a Johnson and Johnson company, in various roles. She was a Regulatory Affairs Project Lead from 2018 to 2020, and before that, she held the position of Senior Regulatory Affairs Specialist from 2016 to 2018. Additionally, she served as Regulatory Affairs Specialist from 2013 to 2015, based in Sommerville, NJ.
Previous Roles at Leading Pharmaceutical Companies
Yashica Narkar has held several roles in major pharmaceutical companies. She was a Global Regulatory Submissions Manager at Takeda Pharmaceuticals in 2016 for 2 months in Springfield, Massachusetts Area. She also worked at Merck as Business & Process Analyst in Global Regulatory Operations in 2013 for 5 months in Rahway, NJ. Furthermore, she had a brief tenure at NeilMed Pharmaceuticals as Regulatory Affairs Specialist from 2012 to 2013, and at BioPharm Inc. as Regulatory and Compliance Associate in 2012.
Education and Expertise
Yashica Narkar's educational background includes a Master of Business Administration in International Business from Goldey-Beacom College, completed from 2013 to 2015. She also holds a Master's degree from Long Island University, where she studied from 2010 to 2012. Additionally, she earned a Bachelor of Pharmacy from LMK College of Agriculture, Kadegaon, completed from 2005 to 2009.
Global Regulatory Affairs Initiatives
Yashica Narkar has led a range of international regulatory initiatives. She executed business strategies and negotiated with Ministries of Health in China, Russia, Thailand, and Tier 1 markets. She conducted MDR Gap assessments, led international remediation programs addressing China TRD and Russia labeling requirements, and managed global regulatory strategy and submission plans for 65 regulated countries. Furthermore, she created project timelines for significant regulatory submissions, including 510k and New Drug Applications (NDA).